SCHEMBL6316864

SCHEMBL6316864

Nc1onc(-c2coc3ccccc23)c1C(=O)NC1CCCc2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RECQL P46063 2/20 0.53
LMNA P02545 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MAPT P10636 1/20 0.50
TSHR P16473 2/20 0.49
TAS1R3 Q7RTX0 5/20 0.48
TAS1R1 Q7RTX1 5/20 0.48
TAS1R2 Q8TE23 5/20 0.48
HTT P42858 1/20 0.47
ALDH1A1 P00352 8/20 0.46
NPSR1 Q6W5P4 1/20 0.46
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
HSD17B10 Q99714 2/20 0.46
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6315929 0.94 RECQL (0.46) RECQLLMNASMN1; SMN2MAPTTSHR
SCHEMBL6320666 0.83 MAOB (0.49) SMN1; SMN2TSHRHTTALDH1A1NPSR1
SCHEMBL6316445 0.83 MAOB (0.52) SMN1; SMN2MAPTTSHRHTTALDH1A1
SCHEMBL6325219 0.82 MAOB (0.54) SMN1; SMN2HTTALDH1A1KDM4ENPC1
SCHEMBL6322682 0.82 MAOB (0.54) SMN1; SMN2HTTALDH1A1KDM4ENPC1
SCHEMBL6317293 0.81 RECQL (0.59) RECQLLMNATSHRTAS1R3TAS1R1
SCHEMBL6319161 0.79 TAS1R3 (0.47) RECQLLMNATSHRTAS1R3TAS1R1
SCHEMBL6315528 0.78 TAS1R3 (0.60) RECQLLMNASMN1; SMN2MAPTTSHR
SCHEMBL6322801 0.78 TAS1R3 (0.55) RECQLSMN1; SMN2TSHRTAS1R3TAS1R1
SCHEMBL6317860 0.78 ALDH1A1 (0.60) RECQLLMNASMN1; SMN2MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 RECQL 2512/4885LMNA 3334/4885SMN1; SMN2 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.